Semaglutide Wegovy® – Tablet

(Commercial Product)

Available Dosage Strengths

1.5 mg | 4 mg | 9 mg | 25 mg

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Semaglutide (Wegovy^®) Injectable (Commercial Product by Novo Nordisk)

Semaglutide Injectable Description^1-3

Semaglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control. The drug is used for the following indications:

For the treatment of obesity and for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults who are obese or overweight.

Mechanism of Action

Mechanism of Action^1-3

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Adverse Reactions

Adverse Reactions^1-3

Common

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia
Headache, dizziness, and injection site reactions

Contraindications & Precautions

Contraindications & Precautions^1-3

Contraindications:

Hypersensitivity to liraglutide or its components
In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2
In patients who are pregnant

Precautions:

In patients with a history of pancreatitis and gallbladder disease
In patients with renal and hepatic impairment

Storage

Refrigerate at 2–8°C (36–46°F) before and during use. Do not freeze. Protect from light and excessive heat.

References

Semaglutide (Wegovy) Prescribing Information Novo Nordisk accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed February 5, 2026
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.

Disclaimer

Wells Pharmacy Network is a 503B-registered outsourcing facility that compounds sterile medications in accordance with current good manufacturing practices (cGMP). Certain FDA-approved products referenced on this site are distributed separately from compounded preparations and are not manufactured by Wells Pharmacy Network. Actual products in stock at time of dispensing may vary due to supply chain variability.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.